Tyrosine kinase inhibitorFDA-approvedFirst-line
Vemurafenib
How it works
Blocks BRAF, a protein involved in cell growth and division, which can help slow down cancer growth.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
Studies show that around 50% of patients with BRAF V600E or V600K mutation achieved an objective response, with a median overall survival of approximately 16.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Treatments for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Melanoma Cells May Develop Resistance to Cancer Drug | Melanoma | lab-study | — | Source → |
| Melanoma Cells Resist Vemurafenib through Mitochondrial Changes | Melanoma | lab-study | — | Source → |
| New Compound May Help Fight Melanoma Resistance | Melanoma | lab-study | — | Source → |
| Vemurafenib May Help Fight Melanoma by Triggering Cell Death | Melanoma | lab-study | — | Source → |
| Researchers Identify New Way to Overcome Resistance to Cancer Treatment | Melanoma | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.